Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-09-21 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第三届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 11th meeting of the 3rd Board of Directors of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and voting results on various proposals, including adjustments to investment projects and the proposal to convene an extraordinary general meeting. The document does not contain financial statements or detailed financial data but rather reports on board decisions and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management.
2022-09-21 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司调整部分募投项目内部投资结构的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding Shenzhen BGI Genomics Co., Ltd.'s adjustment of the internal investment structure of certain projects funded by proceeds from a private placement of shares. It references regulatory approvals, specific fundraising details, and adjustments to project investment structures without changing the total investment amount or the use of funds. The document includes detailed financial figures related to the use of raised funds and the approval process by the board, supervisory board, independent directors, and the sponsor institution. It is not a full annual or interim financial report, nor is it a simple announcement or certification. It is a formal audit or verification opinion related to the use of raised funds and compliance with regulatory requirements. Therefore, it fits best under the category of Audit Report / Information (AR). H1 2022
2022-09-21 Chinese
独立董事关于第三届董事会第十一次会议相关事项的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from independent directors regarding a board meeting decision about adjusting internal investment structures of certain fundraising projects. It references compliance with stock exchange listing rules and company articles but does not contain financial statements or detailed financial data. It is a governance-related document reflecting board oversight and approval of corporate actions. The document length is short (539 characters), and it is not a full report or announcement of voting results. It fits best under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on corporate governance issues.
2022-09-21 Chinese
第三届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the 12th meeting of the 3rd Supervisory Board of Shenzhen BGI Genomics Co., Ltd. It details the meeting's convening, attendance, and the approval of an internal investment structure adjustment related to a fundraising project. The document is an official meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed financial analysis, nor is it a shareholder voting result or a management change announcement. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-09-21 Chinese
关于控股子公司产品获得英国MHRA注册的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the registration of products by a controlling subsidiary with the UK MHRA (Medicines & Healthcare products Regulatory Agency). It details product information, market situation, and potential impact on the company. There are no financial statements, no mention of quarterly or annual results, no voting results, no management changes, no legal proceedings, no financing updates, and no other report types. The document is relatively short (1797 characters) and serves as a regulatory announcement about product registration and market impact. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-20 Chinese
关于收到监事会向董事会提议召开临时股东大会的提议函的公告
Board/Management Information Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the receipt of a proposal from the Supervisory Board to convene an extraordinary general meeting (EGM) to elect a new non-employee representative supervisor due to a resignation. It details the resignation, the nomination of a candidate, and the procedural steps to be taken. There are no financial statements or detailed financial data presented. The document is primarily about board/supervisory changes and the proposal to hold a shareholders' meeting for this purpose. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2022-09-16 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.